Melinta Therapeutics has hired ScinoPharm to provide commercial manufacturing of delafloxacin, the active pharmaceutical ingredient (API) for Baxdela. Baxdela is Melinta’s new drug for the treatment of acute bacterial skin and skin structure infections (ABSSSI) approved by the FDA. The API will be made at ScinoPharm’s Tainan, Taiwan facility. “ScinoPharm is proud of the productive partnership with Melinta by being its sole API supplier of delafloxacin during Baxdela ’s launch,” said Yung F...